Physician profile
Stuart R Seiff
NPI 1114928561
$18,761.90
in general payments reported to CMS, 2019-2025
12 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,450 · 2020: $187 · 2021: $23.53 · 2022: $261 · 2023: $112 · 2024: $8,551 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,550 · Travel and Lodging: $706 · Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,550.00 |
| Travel and Lodging | $705.60 |
| Food and Beverage | $585.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $9,315.86 | 2019-2023 | Tepezza |
| Genentech USA, INC. | $7,174.12 | 2024 | Enspryng |
| Genentech, INC. | $1,350.00 | 2024 | Enspryng |
| Sight Sciences, INC. | $260.62 | 2022 | |
| Galderma Laboratories, L.P. | $146.94 | 2020 | |
| Mallinckrodt Enterprises LLC | $119.97 | 2019 | |
| Allergan, INC. | $109.68 | 2019 | |
| Abbvie INC. | $91.84 | 2023-2024 | Durysta |
| Stryker Corporation | $78.52 | 2025 | Na |
| Revance Therapeutics, INC. | $52.11 | 2025 | Daxxify |
| Amgen INC. | $46.82 | 2025 | Tepezza |
| Merz North America, INC. | $15.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Seiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.